July 1, 2003Open Access

Design and Statistical Aspects of the African American Study of Kidney Disease and Hypertension (AASK)

Q: What is the clinical evidence from this study?

Study design: RCT. Population: Hypertensive kidney disease. Intervention: Ramipril, amlodipine, or metoprolol; lower BP goal (MAP ≤92 mmHg) vs usual BP goal (MAP 102-107 mmHg) vs. Active comparators and different BP goals. Primary outcome: Rate of change in renal function as measured by GFR, assessed by (125) I-iothalamate clearance.

Key Result

The AASK trial is designed to evaluate the effectiveness of three anti-hypertensive drug regimens and two levels of blood pressure control on the progression of hypertensive kidney disease.

Study Design

Type

RCT

Randomization

Randomized

Multicenter

Yes

Structured PICO

Do specific anti-hypertensive drug regimens (ramipril, amlodipine, metoprolol) and lower blood pressure goals improve the rate of change in renal function in African-Americans with hypertensive kidney disease?

Population

African-American men and women aged 18 to 70 yr who have hypertensive kidney disease and GFR between 20 and 65 ml/min per 1.73 m(2)

Intervention

Three anti-hypertensive drug regimens (ramipril, amlodipine, or metoprolol) as initial therapy, and two levels of BP control (lower goal: mean arterial pressure ≤92 mmHg, usual goal: mean arterial pressure 102 to 107 mmHg)

Comparator

Comparison between the three drug regimens and the two BP control goals

Outcome

Rate of change in renal function as measured by GFR, assessed by (125) I-iothalamate clearancesurrogate

The AASK trial is designed to evaluate the optimal anti-hypertensive regimen and blood pressure target for slowing the progression of hypertensive kidney disease in African-Americans.

Abstract

The African American Study of Kidney Disease and Hypertension (AASK) is a multicenter randomized clinical trial designed to test the effectiveness of three anti-hypertensive drug regimens and two levels of BP control on the progression of hypertensive kidney disease. Participants include African-American men and women aged 18 to 70 yr who have hypertensive kidney disease and GFR between 20 and 65 ml/min per 1.73 m(2). The three anti-hypertensive drug regimens include an angiotensin converting enzyme inhibitor (ramipril), a dihydropyridine calcium channel blocker (amlodipine) or a beta-blocker (metoprolol) as initial therapy. The BP control levels are a lower goal (mean arterial pressure, </=92 mmHg) and a usual goal (mean arterial pressure, 102 to 107 mmHg inclusive). The primary outcome is rate of change in renal function as measured by GFR, assessed by (125) I-iothalamate clearance. The main secondary patient outcome is a composite including the following events: (1) reduction in GFR by 50%, (2) end-stage renal disease, or (3) death.

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Gassman et al. (Tue,) conducted a rct in Hypertensive kidney disease. Ramipril, amlodipine, or metoprolol; lower BP goal (MAP ≤92 mmHg) vs usual BP goal (MAP 102-107 mmHg) vs. Active comparators and different BP goals was evaluated on Rate of change in renal function as measured by GFR, assessed by (125) I-iothalamate clearance. The AASK trial is designed to evaluate the effectiveness of three anti-hypertensive drug regimens and two levels of blood pressure control on the progression of hypertensive kidney disease.

synapsesocial.com/papers/6a1641de512cb4f7828ea9c6 https://doi.org/https://doi.org/10.1097/01.asn.0000070080.21680.cb

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: